Q-omics provides the consensus-scored PROX1 profile across patient tissues and cancer cell-line models. PROX1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PROX1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PROX1 RNA expression shows 18,857 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where PROX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PROX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PROX1 survival associations across molecular data types. PROX1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PROX1 RNA expression–survival associations across cancer types. High PROX1 expression shows unfavorable associations in KIRC, LUAD, KIRP and DLBC, but favorable associations in SKCM and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for PROX1 RNA expression.
This table summarizes PROX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for PROX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PROX1 shows lower tumor expression in KIRC, THCA, KIRP, KICH and UCEC and higher tumor expression in COAD. The KIRC box plot shows higher PROX1 RNA expression in normal versus tumor tissue (log2 FC = −2.974, t-test p < 0.001).
This table shows molecular features associated with PROX1 in patient tissues and cancer cell lines. In patient samples, PROX1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PROX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
